Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer

Helit Cohen, Rotem Ben-Hamo, Moriah Gidoni, Ilana Yitzhaki, Renana Kozol, Alona Zilberberg, Sol Efroni

Research output: Contribution to journalArticlepeer-review


Introduction: GATA binding protein 3 (GATA3) is a regulator of mammary luminal cell differentiation, and an estrogen receptor (ER) associated marker in breast cancer. Tumor suppressor functions of GATA3 have been demonstrated primarily in basal-like breast cancers. Here, we focused on its function in luminal breast cancer, where GATA3 is frequently mutated, and its levels are significantly elevated. Methods: GATA3 target genes were identified in normal- and luminal cancer- mammary cells by ChIP-seq, followed by examination of the effects of GATA3 expressions and mutations on tumorigenesis-associated genes and processes. Additionally, mutations and expression data of luminal breast cancer patients from The Cancer Genome Atlas were analyzed to characterize genetic signatures associated with GATA3 mutations. Results: We show that some GATA3 effects shift from tumor suppressing to tumor promoting during tumorigenesis, with deregulation of three genes, BCL2, DACH1, THSD4, representing major GATA3-controlled processes in cancer progression. In addition, we identify an altered activity of mutant GATA3, and distinct associated genetic signatures. These signatures depend on the functional domain mutated; and, for a specific subgroup, are shared with basal-like breast cancer patients, who are a clinical group with regard to considerations of mode of treatment. Conclusions: The GATA3 dependent mechanisms may call for special considerations for proper prognosis and treatment of patients.

Original languageEnglish
Article number464
Pages (from-to)464
JournalBreast Cancer Research
Issue number6
StatePublished - 20 Nov 2014

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer'. Together they form a unique fingerprint.

Cite this